Statins and Inflammation: New Therapeutic Opportunities in Psychiatry
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Statins, which are widely used to treat hypercholesterolemia, have anti-inflammatory and anti-oxidant effects. These are thought to be responsible for the potential effects of statins on various psychiatric disorders. In this study, we comprehensively review the literature to investigate the effects of statins on various psychiatric disorders including depression, schizophrenia, and dementia. In addition, we review adverse effects and drug interactions of statins to give clinically useful information guiding statin use in the psychiatric field. Statins seem useful in reducing depression, particularly in patients with physical disorders such as cardiovascular disease. In patients with schizophrenia, negative symptoms may be reduced by adjuvant statin therapy. Studies on cohorts at risk for dementia have generally shown protective effects of statins, while those on treatment for dementia show inconsistent results. In conclusion, statins used in combination with conventional psychotropic medications may be effective for various psychiatric disorders including depression, schizophrenia, and dementia. Further study is required to determine optimal doses and duration of statin use for the treatment of psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“Neurocognitive impairment following the initiation of statins appears to depend on statin type; lipophilic statins are associated with more cognitive impairments (159, 166), while clinical trials using hydrophilic statins, which are less likely to cross the blood brain barrier, did not show any significant cognitive i…”
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Effects of stress throughout the lifespan on the brain, behaviour and cognition
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2639 · Cited by 6,256 · cited 1×
“Psychiatric conditions are consistently linked to disruptions in the body’s stress response system (mainly the Autonomic Nervous System (ANS) and the HypothalamicPituitary-Adrenal (HPA) axis (31) and are often associated with a pro-inflammatory profile (32).”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177 · cited 1×
“It is known that individuals with psychiatric disorders tend to have unhealthier lifestyle habits, such as drinking excessive amounts of alcohol, are more likely to smoke, eat an unhealthy diet and be more physically inactive than their peers, be less compliant with medication regimens and have poorer self-care (30).”
BackgroundStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Inflammation is detrimental for neurogenesis in adult brain
Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z., & Lindvall, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234031100 · Cited by 1,559
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · cited 1×
“Additionally, high-dose statins increased the risk of diabetes compared to that associated with standard-dose statins (146).”
BackgroundRegulation of the Hypothalamic-Pituitary-Adrenal Axis by Cytokines: Actions and Mechanisms of Action
TURNBULL, A. V., & RIVIER, C. L. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.1 · Cited by 1,297
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Penninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839 · cited 1×
“Psychiatric disorders are often associated with several somatic consequences, including hypertension, heart disease, stroke, cancer, obesity, diabetes mellitus, and osteoporosis (29).”
BackgroundRidker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Bidirectional Association Between Depression and Metabolic Syndrome
Pan, A., Keum, N., Okereke, O. I., Sun, Q., Kivimaki, M., Rubin, R. R., & Hu, F. B. (2012) · Diabetes Care · doi:10.2337/dc11-2055 · Cited by 772
Cholesterol metabolism and homeostasis in the brain
Zhang, J., & Liu, Q. (2015) · Protein & Cell · doi:10.1007/s13238-014-0131-3 · Cited by 686 · cited 3×
“Thus, any brain lipidlowering effect of statins may be very slow (13, 181).”
BackgroundThe role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Self-citationMoylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Self-citationNissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522
Berk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424 · cited 1×
“Although the serum levels of hepatic transaminases may increase in patients taking statins, routine measurement of liver enzyme levels is not required (153).”
BackgroundCan bipolar disorder be viewed as a multi-system inflammatory disease?
Leboyer, M., Soreca, I., Scott, J., Frye, M., Henry, C., Tamouza, R., & Kupfer, D. J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.049 · Cited by 417 · cited 1×
“When considering bipolar disorder as a multisystemic inflammatory disease (131), it is important to examine the effect of statins on the manic phase as well as the depressive phase.”
BackgroundHaag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 1×
“Previous research on the association between statin use and AD, derived from cardiovascular studies, suggested that elective statin use has a beneficial effect on AD (115).”
BackgroundHeart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
Waters, D. D., Ho, J. E., DeMicco, D. A., Breazna, A., Arsenault, B. J., Wun, C.-C., Kastelein, J. J., Colhoun, H., & Barter, P. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.047 · Cited by 333
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322 · cited 1×
“Peripheral pro-inflammatory cytokine signals are transmitted to the CNS via both humoral and neural pathways and may trigger depression by increasing oxidative stress (46); interacting with the hypothalamic–pituitary– adrenal axis; causing impairments in neurotransmitter systems involving glutamate, serotonin, dopamin…”
BackgroundThe dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ
Zheng, C., Zhou, X.-W., & Wang, J.-Z. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0054-4 · Cited by 292
Haroon, E., Daguanno, A. W., Woolwine, B. J., Goldsmith, D. R., Baer, W. M., Wommack, E. C., Felger, J. C., & Miller, A. H. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.026 · Cited by 291
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267 · cited 1×
“Furthermore, cholesterol homeostasis may significantly affect the synthesis, deposition, and clearance of β-amyloid plaques (111, 112).”
BackgroundA randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy
Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.016 · Cited by 200
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Statins, cognition, and dementia-systematic review and methodological commentary
Power, M. C., Weuve, J., Sharrett, A. R., Blacker, D., & Gottesman, R. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.35 · Cited by 150 · cited 1×
“However, RCTs assessing cognition in AD patients have yielded inconsistent results (127).”
ResultNikkheslat, N., Zunszain, P. A., Horowitz, M. A., Barbosa, I. G., Parker, J. A., Myint, A.-M., Schwarz, M. J., Tylee, A. T., Carvalho, L. A., & Pariante, C. M. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.02.002 · Cited by 147 · cited 1×
“Increased inflammatory activity interferes with HPA axis regulation, altering cortisol secretion and feedback, leading to a progressive feedforward loop of inflammation-related conditions (38).”
BackgroundVogelzangs, N., Beekman, A. T., van Reedt Dortland, A. K., Schoevers, R. A., Giltay, E. J., de Jonge, P., & Penninx, B. W. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.9 · Cited by 133
Wysokiński, A., Strzelecki, D., & Kłoszewska, I. (2015) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.004 · Cited by 120 · cited 1×
“The lipid-lowering effects of statins may alleviate symptoms of schizophrenia, because studies have suggested associations between hyperlipidemia and the pathophysiology of schizophrenia (99, 100).”
BackgroundSalagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J., & Berk, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.047 · Cited by 117
Self-citationStatins use and risk of depression: A systematic review and meta-analysis
Parsaik, A. K., Singh, B., M. Hassan, M., Singh, K., Mascarenhas, S. S., Williams, M. D., Lapid, M. I., Richardson, J. W., West, C. P., & Rummans, T. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.026 · Cited by 100
Ghanizadeh, A., & Hedayati, A. (2013) · Depression and Anxiety · doi:10.1002/da.22195 · Cited by 81
Gougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., Yekehtaz, H., & Akhondzadeh, S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578160 · Cited by 77
Statin use and risk of depression: a Swedish national cohort study
Redlich, C., Berk, M., Williams, L. J., Sundquist, J., Sundquist, K., & Li, X. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0348-y · Cited by 76
Self-citationAbbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.049 · Cited by 70
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67 · cited 2×
“One study found that pravastatin significantly decreased the PANSS positive subscale scores, commencing at week 6, in schizophrenia patients, but the decrease failed to remain significant to 12 weeks (87).”
BackgroundHaghighi, M., Khodakarami, S., Jahangard, L., Ahmadpanah, M., Bajoghli, H., Holsboer-Trachsler, E., & Brand, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.018 · Cited by 65
Cited by
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
Self-citationStatins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
Self-citationRepurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Metadata
- Authors
- Kim, S.-W., Kang, H.-J., Jhon, M., Kim, J.-W., Lee, J.-Y., Walker, A. J., Agustini, B., Kim, J.-M., & Berk, M.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-03-05
- Volume
- 10
- Pages
- 103-103
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2916641014
- Cited by
- 136
- References
- 54
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.